Research across Cancer
Related studies from across the Cancer family.
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma
Lung cancer can mimic common lung diseases in young men
This case report and review of the literature describes a 33-year-old male with gastric adenocarcinoma and pulmonary lymphangitic carcinomat…
A 33-year-old man with a lung condition that looked like a common disease was actually a rare form of cancer.
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
Delayed margin formation in lung tumor microwave ablation may occur despite lack of immediate intraprocedural margin
Microwave ablation of lung tumors may show delayed results
This case report describes a single patient with a metastatic lung tumor treated with CT-guided microwave ablation. A well-defined margin ap…
A lung tumor may not show immediate signs of treatment success, but a delayed response can still indicate the procedure worked.
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.